Literature DB >> 25276315

Low dose four-dimensional computerized tomography with volume rendering reconstruction for primary hyperparathyroidism: How I do it?

Timothy A Platz1, Moshim Kukar1, Rania Elmarzouky1, William Cance1, Ahmed Abdelhalim1.   

Abstract

Modification of 4-dimensional computed tomography (4D-CT) technique with volume rendering reconstructions and significant dose reduction is a safe and accurate method of pre-operative localization for primary hyperparathyroidism. Modified low dose 4D-CT with volume rendering reconstructions provides precise preoperative localization and is associated with a significant reduction in radiation exposure compared to classic preoperative localizing techniques. It should be considered the preoperative localization study of choice for primary hyperparathyroidism.

Entities:  

Keywords:  Medical imaging; Nuclear medicine; Radiology

Year:  2014        PMID: 25276315      PMCID: PMC4176789          DOI: 10.4329/wjr.v6.i9.726

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  17 in total

1.  Parathyroid lesions: characterization with dual-phase arterial and venous enhanced CT of the neck.

Authors:  A R Gafton; C M Glastonbury; J D Eastwood; J K Hoang
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-12       Impact factor: 3.825

2.  Converting dose-length product to effective dose at CT.

Authors:  Walter Huda; Kent M Ogden; Mohammad R Khorasani
Journal:  Radiology       Date:  2008-09       Impact factor: 11.105

3.  Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism.

Authors:  Joaquin Gómez-Ramírez; Juan Jose Sancho-Insenser; Jose Antonio Pereira; Jaime Jimeno; Assumpta Munné; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2010-07-14       Impact factor: 3.445

4.  Diagnostic accuracy of 4D-CT for parathyroid adenomas and hyperplasia.

Authors:  J L Chazen; A Gupta; A Dunning; C D Phillips
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-01       Impact factor: 3.825

5.  Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography.

Authors:  Steven E Rodgers; George J Hunter; Leena M Hamberg; Dawid Schellingerhout; David B Doherty; Gregory D Ayers; Suzanne E Shapiro; Beth S Edeiken; Mylene T Truong; Douglas B Evans; Jeffrey E Lee; Nancy D Perrier
Journal:  Surgery       Date:  2006-10-02       Impact factor: 3.982

6.  Determinants of Tc-99m sestamibi SPECT scan sensitivity in primary hyperparathyroidism.

Authors:  Todd W Swanson; Simon K Chan; Steven J Jones; Samuel Bugis; Robert Irvine; Allan Belzberg; Daniel Levine; Sam M Wiseman
Journal:  Am J Surg       Date:  2010-05       Impact factor: 2.565

7.  Contrast-enhanced MDCT characteristics of parathyroid adenomas.

Authors:  Geneva J Randall; Philip B Zald; James I Cohen; Bronwyn E Hamilton
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

8.  Parathyroid imaging: comparison of high-resolution CT and high-resolution sonography.

Authors:  D D Stark; G A Gooding; A A Moss; O H Clark; C O Ovenfors
Journal:  AJR Am J Roentgenol       Date:  1983-10       Impact factor: 3.959

9.  Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi parathyroid scintigraphy.

Authors:  Damita L Thomas; Twyla Bartel; Yusuf Menda; James Howe; Michael M Graham; Malik E Juweid
Journal:  Clin Nucl Med       Date:  2009-10       Impact factor: 7.794

10.  Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism.

Authors:  George J Hunter; Dawid Schellingerhout; Thinh H Vu; Nancy D Perrier; Leena M Hamberg
Journal:  Radiology       Date:  2012-07-12       Impact factor: 11.105

View more
  1 in total

Review 1.  Will 18F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging?

Authors:  Luca Giovanella; Lorenzo Bacigalupo; Giorgio Treglia; Arnoldo Piccardo
Journal:  Endocrine       Date:  2020-09-06       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.